Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Repligen
Repligen
Activities:
Distribution
Manufacturing
Pharmaceutical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
Purolite and Repligen launch a novel CH1 affinity resin for the purification of specialised mAbs
They launch Praesto CH1 a novel 70μm agarose-based affinite resin designed to purified specialised mAbs such as bispecifics or recombinant antibody fragments
Manufacturing
Sartorius and Repligen combine technologies for integrated bioreactor system
The two companies have incorporated Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor to simplify upstream process intensification
Manufacturing
Repligen partners with Daylight on mid-infrared tech
Through this agreement, Repligen will assume responsibility for the commercialisation of DRS Daylight’s Culpeo product
Manufacturing
Repligen plans Polymem acquisition to expand hollow fibre capabilities
The CDMO has made the acquisition to significantly expands hollow fibre membrane and module production capabilities for both industrial and bioprocessing markets
Manufacturing
Sartorius and Repligen collaborate on perfusion-enabled bioreactors
Joint technology to control cell growth, fluid management and cell retention would simplify development and cGMP manufacture of biological drugs
Manufacturing
Repligen completes expansion of US manufacturing facility in Massachusetts
More than doubles capacity for OPUS pre-packed chromatography columns
Manufacturing
Repligen to buy Novozymes Biopharma Sweden
Creates leading supplier of products for manufacturing biologic drugs
Subscribe now